Cel Sci Corporation (CVM)

[lightrock]

@george

That isn't exactly a marker "target"

It is an effect

“It is important to note that the tumours of the Multikine-treated responders in our prior Phase II studies had no HLA Class II expressed on the cell surface following Multikine treatment as compared to controls. This points to Multikine’s ability to modulate HLA expression on the tumour cell surface, thereby allowing the immune system to recognize and attack the tumour.”

I suppose that if there are tumors with no HLA Class II expressed to begin with, then it is a marker/target.

Hmn... maybe...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489746/